The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The innovative eyedrop targets inflammation and pain following ocular surgery
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Subscribe To Our Newsletter & Stay Updated
